The First Global Forum on Bacterial Infections calls for urgent action to contain antibiotic resistance

Expert Review of Anti-Infective Therapy

Volumn 10, Issue 2, 2012, Pages 145-148

  Vlieghe, Erika ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

Author keywords

access; antibiotic resistance; bacterial infection; Delhi; global forum

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; CONFERENCE PAPER; DEVELOPING COUNTRY; DRUG USE; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; INFECTION CONTROL; INFECTION RISK; MEDICAL ASSESSMENT; MULTIDRUG RESISTANCE; TREATMENT INDICATION;

BACTERIA; BACTERIAL INFECTIONS; DEVELOPING COUNTRIES; DRUG RESISTANCE, MICROBIAL; HUMANS; INDIA; POPULATION SURVEILLANCE; PUBLIC HEALTH;

EID: 84857559379     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.162     Document Type: Conference Paper

References (13)

1. Zaidi AK, Huskins WC, Thaver D, Bhutta ZA, Abbas Z, Goldmann DA. Hospital-acquired neonatal infections in developing countries. Lancet 365, 1175-1188 (2005).
2. Bang AT, Bang RA, Baitule SB, Reddy MH, Deshmukh MD. Effect of home-based neonatal care and management of sepsis on neonatal mortality: field trial in rural India. Lancet 354, 1955-1961 (1999).
3. Grundmann H, Klugman KP, Walsh T et al. A framework for global surveillance of antibiotic resistance. Drug Resist. Updat. 14, 79-87 (2011).
4. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10, 597-602 (2010).
5. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. 11, 355-362 (2011).
6. Walsh TR, Toleman MA. The emergence of pan-resistant Gram-negative pathogens merits a rapid global political response. J. Antimicrob. Chemother. doi:10.1093/jac/ dkr378 (2011) (Epub ahaead of print).
7. Morgan DJ, Okeke IN, Laxminarayan R, Perencevich EN, Weisenberg S. Non-prescription antimicrobial use worldwide: a systematic review. Lancet Infect. Dis. 11, 692-701 (2011).
8. Daza P, Banda R, Misoya K et al. The impact of routine infant immunization with Haemophilus influenzae type b conjugate vaccine in Malawi, a country with high human immunodeficiency virus prevalence. Vaccine 24, 6232-6239 (2006).
9. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349, 1341-1348 (2003).
10. Kyaw MH, Lynfield R, Schaffner W et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med. 354,1455-1463 (2006).
11. Laxminarayan R, Ganguly NK. India's vaccine deficit: why more than half ofIndian children are not fully immunized, and what can -and should -be done. Health Aff. (Millwood) 30, 1096-1103 (2011).
12. Bartram J, Cairncross S. Hygiene, sanitation, and water: forgotten foundations of health. PLoS Med. 7, e1000367 (2011).
13. Ganguly NK, Arora NK, Chandy SJ et al. Rationalizing antibiotic use to limit antibiotic resistance in India. Indian J. Med. Res. 134, 281-294 (2011).